NCT00481962

Completed

Health Economic Assessment of Tygacil® in the Treatment of S...

Wyeth is now a wholly owned subsidiary of Pfizer Source

Compare

Other study identifiers

Sponsor study identifier

3074A1-102184

Study Type

observational

Actual enrollment (reported)

180

Locations

1 country

Sites

1

Timeline

Study Start

February 2006

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

December 2008

Actual (reported)

Study Completion

December 2008

Actual (reported)

Brief Summary

The main goals of the study are: Assessment of Tygacil's cost-effectiveness; Process cost analysis from a hospital perspective (including length of stay, treatment costs, side effect management costs, costs of monitoring, costs of diagnostic procedures, cost of care (TISS 10 score etc.); Efficacy of Tygacil under usual care conditions (cure rate).

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 180 participants
Study completion date: December 2008
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
February 2006
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
May 31, 2007
Actual (reported)
First Posted
June 4, 2007
Actual (reported)
Primary Completion
December 2008
Actual (reported)
Study Completion
December 2008
Actual (reported)

Last Updated: September 28, 2009
Status Verified: September 2009
Last Update Submitted: September 25, 2009

Conditions

Peritonitis

Interventions

TygacilDrug

Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

Sampling MethodNon-Probability Sample

Study Population

primary care clinical

You may qualify if:

Diagnosis of secondary peritonitis

Sponsors & Collaborators

Wyeth is now a wholly owned subsidiary of Pfizer
Industrylead

Study Sites (1)

Multiple Cities, Germany

MeSH Terms

Conditions

Peritonitis

Interventions

Tigecycline

Condition Hierarchy (Ancestors)

Intraabdominal InfectionsInfectionsPeritoneal DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

TetracyclinesNaphthacenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

Medical Monitor
Wyeth is now a wholly owned subsidiary of Pfizer
STUDY DIRECTOR
Trial Manager
For Germany, medinfoDEU@wyeth.com
PRINCIPAL INVESTIGATOR

Enrollment

180 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: INDUSTRY

Study Record Dates

First Submitted

May 31, 2007

First Posted

June 4, 2007

Study Start

February 2006

Date type not reported

This date has not been verified as actual or estimated.

NCT00136201

Study Comparing Tigecycline and Imipenem/Cilastatin in Chinese Subjects With Complicated Intra-Abdominal Infections

Phase 3Completed

NCT00488761

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cSSSI

Phase 4Completed

NCT00488306

Study Evaluating the Safety and Efficacy of Tigecycline in Hospitalized Patients With cIAI

Phase 4Completed

NCT00376324

Study Evaluating the Pharmacokinetics of Tigecycline in Human Bone

Phase 1Completed

NCT01531543

Prospective Comparison of Primary Abdominal Closure and Vacuum Assisted Laparostomy in Treatment of Severe Peritonitis

Phase 4Completed

NCT00406237

Pharmacokinetic Study Of Tigecycline In Adult Subjects With Primary Biliary Cirrhosis

Phase 1Completed

Treatment in an ICU

Patient age \>18 years

Contact the study team to confirm eligibility.

Organic Chemicals

Polycyclic Compounds

Primary Completion

December 2008

Actual (reported)

Study Completion

December 2008

Actual (reported)

Last Updated

September 28, 2009

Record last verified: 2009-09

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00481962
Data provider: ClinicalTrials.gov
Source updated: 2009-09-28
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:27:33 UTC

Locations

DE(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Source record

Locations